This review will only focus on inherited platelet disorders (IPDs) that are caused by dysfunctions in platelet formation and function associated with bleeding or not. expected to decrease time to diagnosis, increase the diagnostic rate, and they have provided novel insights into the genotype-phenotype correlation of IPDs. Some of these approaches have also focused on the discovery of novel genes and unexpected molecular pathways which modulate megakaryocyte and platelet biology were discovered. A growing number of genetic defects underlying IPDs have been identified and we will here provide an overview of the diverse molecular players. Screening of these genes will deliver a genetic diagnosis for about 40%-50% of the IPDs patients and we will compare different HTS applications that have been developed. A brief focus on gene variant interpretation and classification in a diagnostic setting will be given. Although it is true that successes in diagnostics and gene discovery have been reached, a large fraction of patients still remains without a conclusive diagnosis. In these patients, the sum of non-diagnostic variants in known genes or in potential novel genes might only be proven informative in future studies with larger patient cohorts and by data sharing among the diverse genome medicine initiatives. Finally, we still do not understand the role of the non-coding genome space for IPDs.
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| FROM C AND IDATE G ENE SCREENING TO HI G H -THROUG HPUT S EQUEN CING FOR D IAG NOS TI C S OF INHERITED PL ATELE T DISORDER S
Molecular diagnosis of IPDs has proven to be challenging and, in the past, required intensive laboratory work-up to narrow down the list of candidate genes potentially harboring the causal variants. A single gene or shortlist of plausible genes was put forward based on these results to screen for pathogenic variants using Sanger sequencing.
This approach in combination with linkage and chromosomal analysis have revealed the molecular basis of 42 IPDs since 1990 ( Figure 1 ).
The advent of high-throughput sequencing (HTS) in 2011 has transformed the field with, since its moment of implementation, a growing spectrum of 24 additional IPDs as discussed further in a section on IPDs and HTS gene discoveries (Figure 1 ). On the other hand, HTS has entered the diagnostic field for IPDs with mainly targeted gene panels and whole-exome sequencing (WES). While whole genome sequencing (WGS) has its advantages, it is only now making its way from research to the clinical diagnostics. Wet labs nowadays play a different, but still crucial role in diagnostics often by confirming the pathogenicity of variants found via HTS. Different groups have made efforts in developing HTS platforms for the molecular diagnosis of IPD patients as summarized in Table 1 and Figure 2 .
The international HTS initiative ThromboGenomics (thrombo.
cambridgednadiagnosis.org.uk) opted for a custom capture of known genes (so-called TIER1 genes) implicated in bleeding, thrombotic, and platelet disorders (63 genes in published version, 5 95 genes in updated version 6 ) to allow deeper coverage and multiplexing of samples to achieve rapid and cost-effective diagnostics for IPDs.
Detected variants are filtered using their minor allele frequency in As HTS is becoming more affordable, WGS has become feasible and will in time take over from over panel sequencing and WES. The main difficulty will be the analysis of the big data and variant interpretation. In the UK, the 100 000 Genomes (GEL) project 14 is paving the way forward to implement WGS for clinical diagnostics. The NIHRRare Disease initiative that include the subproject BRIDGE-BPD 6, 8 was the pilot study of GEL that started in 2012 for WGS patients with bleeding, thrombotic, and platelet disorders (BPD) of unknown etiology with the aim of gene discovery and diagnostics (Table 1) .
To date, the project has included 1916 IPD patients and for 106 of them pathogenic variants were identified. 6 Similar as for the studies described above, BRIDGE-BPD findings were more successful for thrombocytopenia cases than the less specified IPD. This review will not further elaborate on the characteristics of all these IPDs but will focus on the contributions of HTS technologies that added novel genes to these pathologies (blue genes in Figure 3 ).
Most genes defects result in bleeding and thrombocytopenia, but some are also associated with abnormal erythrocyte development or defects in myeloid or white blood cells. In addition, quite some gene defects (underlined genes in Figure 3 ) do result in non-blood phenotypes where the platelet phenotype is part of a syndrome.
Defects in early megakaryopoiesis have been well documented
where mainly thrombopoietin and its receptor MPL together with some specific transcription factors regulate these early processes.
Variants in these genes result in thrombocytopenia with platelet dysfunction. WES identified recessive variants in the thrombopoietin gene THPO for 2 siblings with aplastic anemia while heterozygous carriers had mild thrombocytopenia. 24 Severe thrombocytopenia with progression to aplastic anemia is also present in patients with recessive MPL variants although heterozygous parents have normal platelet counts. WES also expanded the spectrum of thrombocytopenia related to defects in transcription factors that mediate megakaryopoiesis with dominant variants in ETV6 25 , GFI1B 26 , and MECOM.
27
ETV6 variants in the ETS domain are shown as cause for thrombocytopenia with leukemic predisposition and mild platelet dysfunction. 25 
Dominant variants in GFI1B strongly mimic X-linked GATA1 deficiency
with macrothrombocytopenia and platelets with fewer alpha granules and dyserythropoiesis. 26 Radioulnar synostosis with a megakaryo- . 28 These variants are the first example of non-coding elements that contribute to IPDs and they were covered in exomes.
The later stages of megakaryopoiesis with proplatelet formation and trafficking of granules from the megakaryocyte to these proplatelets can be altered by molecular defects related to proteins that regulate granule formation and trafficking and by proteins that define the cytoskeletal structures. More than half of the genes found to be involved in granulopoiesis cause HPS, which involves oculocutaneous albinism, lysosomal storage defects and a bleeding tendency due to dense granule defects. In addition to the 8 known HPS genes, WES more recently identified 2 additional genes. A homozygous nonsense mutation was identified in BLOC1S6 (PLDN) in a HPS (referred to as type 9) patient who also suffered from leucopenia and recurrent infections. 29 Finally, HPS type 10 was reported which encompasses an immune (neutropenia and immunodeficiency) and neurological (mental disability, microcephaly, and seizures) phenotype with albinism but remarkably no bleeding. 30 Functional platelet studies could not be performed for this patient and the authors speculate that the patient might have a platelet granule defect that was overlooked because it was a minor part of the clinical phenotype. Pathogenic variants were present in AP3D1, a subunit of the AP3 complex, which is known to be involved in HPS. Variants in AP3B1, another subunit of this adaptor protein complex, were reported as cause of HPS type 2, which also involves immune, but no obvious neurological defects. The first IPD identified by WES is the Gray platelet syndrome with recessive variants in NBEAL2 as cause. 31 Patients typically present with macrothrombocytopenia and gray platelets have bleeding symptoms and often splenomegaly but some patients also have other features that mimic autoimmune lymphoproliferative syndrome. NBEAL2 is a BEACH-containing protein (named after "Beige and Chediak-Higashi"), a conserved ~280 residue domain, that is, present in 9 other human BEACH domaincontaining proteins, of which 2 (NBEA and LYST) have previously been found to cause platelet dense granule defects in IPD syndromes (autism and Chediak-Higashi syndrome, respectively).
Different genes have now been shown to be involved in the megakaryocyte cytoskeletal structure and variants cause reorganization with mainly defects in proplatelet formation that cause thrombocytopenia with but also without bleeding symptoms as F I G U R E 4 Timeline of techniques to establish molecular diagnosis. The number of IPD genes discovered in a certain period is indicated with the different colors representing the methodology used some thrombocytopenia patients were identified during routine hematological investigations. Most of the genes for these cytoskeletal defects were discovered via WES except for the non-coding gene The role of CDC42 in patient-derived megakaryocytes has not been studied. Using a different approach and combining WES with SimReg analysis, multisystem phenotypes are taken into account via HPOlabeling and their association with the genotype is modeled. 16 As such, a premature stop codon in the DIAPH1 gene could be associated with macrothrombocytopenia, hearing loss, and bleeding. 36 It is a GOF variant that increased actin polymerization and abnormal actin structures with decreased proplatelet formation was found in patient-derived megakaryocytes. A third form of inherited "micro"thrombocytopenia (in addition to WAS and ARPC1B) and bleeding was found to be due to recessive variants in FYB (or ADAP).
37
Bone marrow aspirate from 1 patient showed reduced numbers of mature multilobulated megakaryocytes and increased megakaryocytes with nuclear hypersegmentation, suggesting abnormal maturation of megakaryocytes. The adaptor protein ADAP has a role in actin reorganization although this function was not further studied in 44 It is not clear why the platelet phenotype was not mentioned before or whether there is a specific association with the type of GNE variant and having a platelet phenotype. GNE codes for the UDP-N-acetylglucosamine-2-epimerase/N-acetylmannosamine kinase, that is, essential for sialic acid modification of glycoproteins and glycolipids, a process largely unstudied in megakaryopoiesis.
Finally, some gene defects only result in a functional platelet defect often associated with bleeding but these do not affect platelet counts. In this class, only one gene was added to the list using WES, namely recessive RASGRP2 (or CalDAG-GEFI) variants as cause for a Glanzmanns thrombasthenia-like platelet phenotype. 45 The resulting CalDAG-GEFI can no longer aid platelet spreading and thrombus formation under flow. Such receptor-mediated signaling cascades are of tremendous importance for platelets, which lack a nucleus, and need a fully equipped cell surface to be able to function properly.
| CON CLUS I ON S AND FUTURE CHALLENG E S
Genome medicine is rapidly moving forward and Figure 4 illustrates the different genetic technologies that were used to identify novel genes involved in IPDs. WGS is the most recent technology that has just entered the field but is expected to bring knowledge from the non-coding space for disease. It is clear that HTS and deep phenotyping for the diagnosis of rare IPDs will further expand the gene list. As genes for the most common IPD have been found and often a single family is found for a novel gene, broad data sharing for accurate clinical delineation of previously unrecognized entities would be essential. In the future, with the help of HTS and by examining the non-coding space, novel causes of the extremely heterogeneous group of IPD will be described and insights will be gained on the relation of importance of these findings in megakaryocyte and platelet biology. 
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